Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NBI 921352

Drug Profile

NBI 921352

Alternative Names: NBI-921352; XEN 901

Latest Information Update: 04 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xenon Pharmaceuticals
  • Developer Neurocrine Biosciences; Xenon Pharmaceuticals
  • Class Antiepileptic drugs; Small molecules
  • Mechanism of Action Nav1.6 voltage-gated sodium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epilepsy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Epilepsy
  • Discontinued Dravet syndrome; Seizures

Most Recent Events

  • 04 Dec 2023 Discontinued - Phase-II for Seizures (Adjunctive treatment) in Czech Republic, Spain, Australia, Belgium, France, Italy, United Kingdom (PO) (Xenon pharmaceuticals pipeline, December 2023)
  • 21 Aug 2023 Neurocrine Biosciences completes phase-II trial in Seizures (Adjunctive treatment) in United Kingdom, Hungary, Australia, Belgium, Czech Republic, France, Italy, and Spain (PO) (NCT05159908)
  • 09 Aug 2023 Neurocrine Biosciences has completed enrolment in phase-II trial in Seizures (Adjunctive treatment) in Hungary, United Kingdom, Spain, Czech Republic, Italy, Belgium, France and Australia (PO) (EudraCT 2021-001433-39) (NCT05159908)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top